Tech Company Financing Transactions
Foghorn Therapeutics Funding Round
Foghorn Therapeutics closed a $50 million funding round on 3/15/2018. Investors included Flagship Pioneering.
Transaction Overview
Company Name
Announced On
3/15/2018
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Flagship Pioneering (Douglas Cole)
Proceeds Purpose
The company is in the process of developing drug candidates across a range of cancers and is exploring applications of Gene Traffic Control in neurology and immunology.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 Binney St. 610
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
A Flagship Pioneering company, Foghorn Therapeutics (Nasdaq: FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adrian Gottschalk
Chief Financial Officer
Tess Cameron
Chief Medical Officer
Samuel Agresta
Vice President
Steve Bellon
Vice President
Ho Chan
Vice President
David Millan
Browse more venture capital transactions:
Prev: 3/15/2018: Wefarm venture capital transaction
Next: 3/15/2018: Dragon venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs